|
|
|
|
| LEADER |
01000caa a22002652c 4500 |
| 001 |
NLM355378302 |
| 003 |
DE-627 |
| 005 |
20250304153118.0 |
| 007 |
cr uuu---uuuuu |
| 008 |
231226s2023 xx |||||o 00| ||eng c |
| 024 |
7 |
|
|a 10.1016/j.cej.2022.138781
|2 doi
|
| 028 |
5 |
2 |
|a pubmed25n1184.xml
|
| 035 |
|
|
|a (DE-627)NLM355378302
|
| 035 |
|
|
|a (NLM)37033201
|
| 035 |
|
|
|a (PII)138781
|
| 040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
| 041 |
|
|
|a eng
|
| 100 |
1 |
|
|a Chen, Weiguo
|e verfasserin
|4 aut
|
| 245 |
1 |
0 |
|a Hypoxia-responsive Immunostimulatory Nanomedicines Synergize with Checkpoint Blockade Immunotherapy for Potentiating Cancer Immunotherapy
|
| 264 |
|
1 |
|c 2023
|
| 336 |
|
|
|a Text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a ƒaComputermedien
|b c
|2 rdamedia
|
| 338 |
|
|
|a ƒa Online-Ressource
|b cr
|2 rdacarrier
|
| 500 |
|
|
|a Date Revised 03.07.2023
|
| 500 |
|
|
|a published: Print-Electronic
|
| 500 |
|
|
|a Citation Status PubMed-not-MEDLINE
|
| 520 |
|
|
|a Inducing cell death while simultaneously enhancing antitumor immune responses is a promising therapeutic approach for multiple cancers. Celastrol (Cel) and 7-ethyl-10-hydroxycamptothecin (SN38) have contrasting physicochemical properties, but strong synergy in immunogenic cell death induction and anticancer activity. Herein, a hypoxia-sensitive nanosystem (CSTAP) was designed to demonstrate effective immunotherapy for colorectal cancer by systemic delivery of an immunostimulatory chemotherapy combination. Furthermore, the combination of CS@TAP with anti-PD-L1 mAb (αPD-L1) exhibited a significant therapeutic benefit of delaying tumor growth and increased local doses of immunogenic signaling and T-cell infiltration, ultimately extending survival. We conclude that CS@TAP is an effective inducer of immunogenic cell death (ICD) in cancer immunotherapy. Therefore, this study provides an encouraging strategy to synergistically induce immunogenic cell death to enhance tumor cytotoxic T lymphocytes (CTLs) infiltration for anticancer immunotherapy
|
| 650 |
|
4 |
|a Journal Article
|
| 650 |
|
4 |
|a Cancer immunotherapy
|
| 650 |
|
4 |
|a Covalent organic frameworks
|
| 650 |
|
4 |
|a Immunogenic cell death
|
| 650 |
|
4 |
|a Immunogenic nanomedicine
|
| 700 |
1 |
|
|a Sheng, Ping
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Chen, Yujiang
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Liang, Yi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wu, Sixin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Jia, Liying
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a He, Xin
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Zhang, Chun-Feng
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Wang, Chong-Zhi
|e verfasserin
|4 aut
|
| 700 |
1 |
|
|a Yuan, Chun-Su
|e verfasserin
|4 aut
|
| 773 |
0 |
8 |
|i Enthalten in
|t Chemical engineering journal (Lausanne, Switzerland : 1996)
|d 1999
|g 451(2023), Pt 2 vom: 06. Jan.
|w (DE-627)NLM098273531
|x 1385-8947
|7 nnas
|
| 773 |
1 |
8 |
|g volume:451
|g year:2023
|g number:Pt 2
|g day:06
|g month:01
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1016/j.cej.2022.138781
|3 Volltext
|
| 912 |
|
|
|a GBV_USEFLAG_A
|
| 912 |
|
|
|a SYSFLAG_A
|
| 912 |
|
|
|a GBV_NLM
|
| 912 |
|
|
|a GBV_ILN_350
|
| 951 |
|
|
|a AR
|
| 952 |
|
|
|d 451
|j 2023
|e Pt 2
|b 06
|c 01
|